Ciprofloxacin in critically ill children

Anaesthesia and Intensive Care

Volumn 39, Issue 4, 2011, Pages 635-639

  Sideri, G ^a   Kafetzis, D A ^b   Vouloumanou, E K ^c   Papadatos, J H ^a   Papadimitriou, M ^a   Falagas, M E ^c,d,e  

^a P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^d HENRY DUNANT HOSPITAL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arrhythmia; Bacteraemia; Children; Ciprofloxacin; Toxicity

Indexed keywords

AMIKACIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; METRONIDAZOLE; NETILMICIN; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TIGECYCLINE; TIMENTIN; VANCOMYCIN;

ABDOMINAL PAIN; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ACUTE GRANULOCYTIC LEUKEMIA; ANTIBIOTIC THERAPY; ARTHROPATHY; ARTICLE; BACTERIAL PNEUMONIA; CARDIOMYOPATHY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CHILD DEATH; CHILDHOOD CANCER; CHONDROPATHY; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CRANIENCEPHALIC INJURY; CRITICALLY ILL PATIENT; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN SYNDROME; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTEROBACTER AEROGENES; EPENDYMOMA; FEMALE; FOLLOW UP; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; KIDNEY DYSFUNCTION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LUNG DYSPLASIA; MALE; MULTIPLE ORGAN FAILURE; MYELITIS; PANCREAS PSEUDOCYST; PANCREATITIS; PNEUMOCYSTOSIS; PRESCHOOL CHILD; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QT PROLONGATION; RHEUMATIC FEVER; SERRATIA INFECTION; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS MALTOPHILIA; SUPRAVENTRICULAR TACHYCARDIA; TENDON DISEASE; TERTIARY HEALTH CARE; TRAUMATIC BRAIN INJURY; VOMITING; WISKOTT ALDRICH SYNDROME;

EID: 79960455900     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1103900416     Document Type: Article

References (21)

1. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 2006; 118:1287-1292.
2. Fedler KA, Jones RN, Sader HS, Fritsche TR. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003). Diagn Microbiol Infect Dis 2006; 55:157-164.
3. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7:523-530.
4. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 2005; 103:2629-2635. (Pubitemid 40800544)
5. Petrilli A, Altruda CF, Alberto PPC. Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. Pediatr Blood Cancer 2007; 49:682-686. (Pubitemid 350194435)
6. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 1991; 19:289-296.
7. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use - safety report. Pediatr Infect Dis J 1997; 16:127-129; discussion 160-162.
8. Knorr JP, Moshfeghi M, Sokoloski MC. Ciprofloxacin-induced Q-T interval prolongation. Am J Health Syst Pharm 2008; 65:547-551. (Pubitemid 351429716)
9. Nejjari N, Benomar S, Lahbabi MS. [Nosocomial infections in neonatal and pediatric intensive care. The appeal of ciprofloxacin]. Arch Pediatr 2000; 7:1268-1273.
10. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI M100-S18. Clinical and Laboratory Standards Institute W, PA.
11. Channa HMA, Ashfaq M, Bangash R, Abbasi A, Qureshi MA. Preventive role of zinc chloride against toxicity of ciprofloxacin on the growing cartilage of Wistar albino rat litter. J Ayub Med Coll Abbottabad 2008; 20:77-81.
12. Lozo E, Riecke K, Schwabe R, Vormann J, Stahlmann R. Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats. Antimicrob Agents Chemother 2002; 46:1755-1759. (Pubitemid 34535193)
13. van der Linden PD, van Puijenbroek EP, Feenstra J, Veld BA, Sturkenboom MC, Herings RM et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001; 45:235-239.
14. Saez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002; 21:14-22. (Pubitemid 34073952)
15. Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J 1997; 16:106-111; discussion 123-126.
16. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002; 21:525-529. (Pubitemid 34625833)
17. Calva-Mercado JJ, Castillo G, Lopez-Vidal Y. [Flouroquinolone activity in clinical isolates of Streptococcus pneumoniae with different susceptibility to penicilline: an epidemiological study in five cities of Mexico]. Gac Med Mex 2005; 141:253-258.
18. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006; 57:573-576.
19. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28:123-127.
20. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 Suppl 2:S144-157.
21. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29:374-379. (Pubitemid 46349590)